Xcout Intel
Sparrow Pharmaceuticals competitors & alternatives
The 12 closest competitors and alternatives to Sparrow Pharmaceuticals among pharmaceuticals companies — ranked by similarity to what Sparrow Pharmaceuticals actually does, not by market-cap band.
Subscribe to see Sparrow Pharmaceuticals’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
About Sparrow Pharmaceuticals
Sparrow Pharmaceuticals, Inc. is a Boston-based biopharmaceutical company focused on developing targeted cardiometabolic therapeutics. The company aims to address conditions such as diabetes and endocrine diseases with precision therapies.
Sparrow Pharmaceuticals at a glance
Sparrow Pharmaceuticals is a pharmaceuticals company headquartered in United States. Its most recent funding round, Series A, raised $95M in September 2025. Xcout tracks 16 named people at Sparrow Pharmaceuticals, including Robert Jacks (President & Chief Executive Officer).
Sparrow Pharmaceuticals leadership
- Robert JacksPresident & Chief Executive Officer
- George EldridgeChief Financial Officer
- Dr. David KatzChief Scientific Officer
- FRANK CZERWIECChief Medical Officer
- Dora FerrariSenior Vice President, Development Operations
- Jamie MacPhersonSenior Vice President, Regulatory Affairs & Quality Assurance
10 more named people on record for Sparrow Pharmaceuticals, with roles, board committees and tenure — see the full roster →
Sparrow Pharmaceuticals funding rounds
The 5 most recent:
| Date | Round | Amount | Investors |
|---|---|---|---|
| Series A | $95M | 3 named | |
| SEC Form D filing | $61.8M | — | |
| SEC Form D filing | $10M | — | |
| Series U | $10M | 3 named | |
| — | $50M | 6 named |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Top 12 Sparrow Pharmaceuticals competitors
Ranked by semantic similarity — how close each company is to Sparrow Pharmaceuticals by what it does, using Xcout's live company graph. Click any company for its full profile, or its competitor set.
Similar pharmaceuticals company
Arisaph Pharmaceuticals Inc. is a Boston, Massachusetts-based biopharmaceutical company that utilizes drug discovery platforms to develop novel therapies for cancer, cardiovascular disease, and diabetes. The company's pipeline includes small molecule inhibitors and differentiated medicines aimed at cardiometabolic diseases and oncology.
Similar pharmaceuticals company
Boston Pharmaceuticals is a U.S.-based clinical-stage biopharmaceutical company that acquires, develops, and advances drug candidates for serious diseases. It works with pharmaceutical and biotechnology partners to bring clinical-stage medicines toward commercialization and serves patients with significant unmet medical needs.
pharmaceutical
Yarrow Bioscience is a U.S.-based biotechnology company focused on the development of treatments for autoimmune diseases. The company has been involved in significant pharmaceutical deals, including the acquisition of drug candidates for thyroid conditions.
Similar pharmaceuticals company
Agios Pharmaceuticals, Inc. is a biopharmaceutical company specializing in the discovery and development of treatments within cellular metabolism and associated biological domains. Its lead product, PYRUKYND (mitapivat), serves as an activator for both healthy and various mutated forms of the pyruvate kinase (PK) enzyme, targeting the management of hemolytic anemias. Additionally, AG-946, an investigational compound, is currently undergoing Phase I clinical evaluation for hemolytic anemias and other conditions. Established in 2007, Agios Pharmaceuticals, Inc. is based in Cambridge, Massachusetts.
Similar pharmaceuticals company
SCOHIA PHARMA, Inc. is a clinical-stage specialty bioventure headquartered in Fujisawa, Japan. Established in 2017, the company focuses its research and development on lifestyle-related diseases including cardiovascular, metabolic, and renal disorders.
Similar pharmaceuticals company
Antares Therapeutics, Inc. is a biotechnology company headquartered in Boston, Massachusetts, focused on developing first-in-class precision medicines.
Similar pharmaceuticals company
Corcept Therapeutics Incorporated is a commercial-stage pharmaceutical company that develops and markets cortisol modulation therapies to treat serious medical conditions. The company focuses on modulating cortisol activity at the glucocorticoid receptor to create novel treatments across therapeutic areas such as endocrinology, oncology, metabolism, and neurology.
Similar pharmaceuticals company
Aardvark Therapeutics, Inc. is a biopharmaceutical firm in its clinical development phase, concentrating on developing small-molecule treatments. These therapies are designed to stimulate the body's natural regulatory systems (innate homeostatic pathways) to combat metabolic disorders. The company's primary experimental drug, ARD-101, is an orally administered, gut-specific small molecule. It functions as an agonist, targeting particular bitter taste receptors found within the gut lumen. ARD-101 is currently undergoing a Phase III clinical trial for managing excessive hunger (hyperphagia) associated with Prader-Willi Syndrome. Additionally, it is in a Phase II trial for addressing hyperphagia linked to acquired hypothalamic obesity, often a result of craniopharyngioma treatments like surgery or radiation therapy. Aardvark Therapeutics is also advancing ARD-201, which is currently in Phase I clinical trials for the treatment of obesity. Established in 2017, the company is based in San Diego, California.
Similar pharmaceuticals company
VISEN Pharmaceuticals operates as an investment holding company, concentrating on the development and commercialization of endocrine treatments across mainland China, Hong Kong, and Taiwan. Their flagship product, Lonapegsomatropin, offers a once-weekly, long-acting growth hormone replacement designed for pediatric growth hormone deficiency. The company is also progressing other therapies, such as TransCon CNP (navepegritide), a long-acting prodrug utilizing c-type natriuretic peptide for achondroplasia, and Palopegteriparatide, a daily parathyroid hormone replacement therapy intended for chronic hypoparathyroidism. VISEN has forged strategic collaborations with Shanghai Pharmaceutical and United Family Healthcare. The enterprise was founded in 2018 and is based in Suzhou, China.
Similar pharmaceuticals company
Xeris Biopharma Holdings, Inc. operates as a biopharmaceutical company, focusing on the development and commercialization of therapeutic solutions for individuals across the fields of endocrinology, neurology, and gastroenterology. Its current portfolio includes: Gvoke: A ready-to-administer liquid glucagon designed to treat severe hypoglycemia. Keveyis: A therapy addressing hyperkalemic, hypokalemic, and related forms of primary periodic paralysis. Recorlev: A cortisol synthesis inhibitor approved for managing endogenous hypercortisolemia in adult patients with Cushing's syndrome. Beyond its marketed products, the company maintains an active development pipeline. This pipeline seeks to broaden the applications and indications for existing treatments and introduce novel pharmaceuticals leveraging its proprietary XeriSol and XeriJect formulation technology platforms. Founded in 2005, Xeris Biopharma is headquartered in Chicago, Illinois.
Similar pharmaceuticals company
Madrigal Pharmaceuticals, Inc. is a biopharmaceutical company in the clinical development phase, concentrating its efforts on discovering and commercializing innovative treatments for cardiovascular, metabolic, and liver disorders. Its most advanced drug candidate, resmetirom, functions as a liver-targeted selective thyroid hormone receptor-ß agonist, currently undergoing late-stage (Phase III) clinical trials for managing non-alcoholic steatohepatitis (NASH). The company's pipeline also features MGL-3745, which serves as a secondary or backup compound to resmetirom. Madrigal holds a collaborative agreement with Hoffmann-La Roche, encompassing research, development, and commercialization activities. The company's operations are based out of West Conshohocken, Pennsylvania.
Similar pharmaceuticals company
Danqing Pharmaceuticals is a pharmaceutical company headquartered in Beijing with a U.S. subsidiary in Boston. The company focuses on first-in-class drug discovery and development in oncology, targeting therapeutic areas such as breast, gynecological, and gastrointestinal cancers.
Analyze another company
Search any company we track to see its competitive set.
Or describe a company
Paste a short paragraph describing a company or product — we'll find the most similar companies we track, scored 1–100.
See the full profile of Sparrow Pharmaceuticals and its market
Funding, investors, tech stack, hiring signals, leadership and corporate events — for Sparrow Pharmaceuticalsand every competitor above — in one live dashboard.
Subscribe to Xcout Intel →